134 related articles for article (PubMed ID: 34725192)
1. The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity
Klausz K; Kellner C; Gehlert CL; Krohn S; Wilcken H; Floerkemeier I; Günther A; Bauerschlag DO; Clement B; Gramatzki M; Peipp M
Mol Cancer Ther; 2022 Jan; 21(1):70-78. PubMed ID: 34725192
[TBL] [Abstract][Full Text] [Related]
2. A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic and Antileukemic Nature for Cancer Treatment.
Meier C; Steinhauer TN; Koczian F; Plitzko B; Jarolim K; Girreser U; Braig S; Marko D; Vollmar AM; Clement B
ChemMedChem; 2017 Mar; 12(5):347-352. PubMed ID: 28099785
[TBL] [Abstract][Full Text] [Related]
3. Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer.
Flörkemeier I; Steinhauer TN; Hedemann N; Ölander M; Artursson P; Clement B; Bauerschlag DO
Ther Adv Med Oncol; 2021; 13():17588359211059896. PubMed ID: 34887943
[TBL] [Abstract][Full Text] [Related]
4. High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer.
Flörkemeier I; Steinhauer TN; Hedemann N; Weimer JP; Rogmans C; van Mackelenbergh MT; Maass N; Clement B; Bauerschlag DO
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008166
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
6. The Aza-Analogous Benzo[
Aichinger G; Lichtenberger FB; Steinhauer TN; Flörkemeier I; Del Favero G; Clement B; Marko D
Molecules; 2020 Mar; 25(7):. PubMed ID: 32230817
[TBL] [Abstract][Full Text] [Related]
7. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
8. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Burger R; Le Gouill S; Tai YT; Shringarpure R; Tassone P; Neri P; Podar K; Catley L; Hideshima T; Chauhan D; Caulder E; Neilan CL; Vaddi K; Li J; Gramatzki M; Fridman JS; Anderson KC
Mol Cancer Ther; 2009 Jan; 8(1):26-35. PubMed ID: 19139110
[TBL] [Abstract][Full Text] [Related]
11. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
12. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide.
Kumagai T; Ikezoe T; Gui D; O'Kelly J; Tong XJ; Cohen FJ; Said JW; Koeffler HP
Clin Cancer Res; 2004 Feb; 10(4):1508-20. PubMed ID: 14977855
[TBL] [Abstract][Full Text] [Related]
13. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Leiba M; Jakubikova J; Klippel S; Mitsiades CS; Hideshima T; Tai YT; Leiba A; Pines M; Richardson PG; Nagler A; Anderson KC
Br J Haematol; 2012 Jun; 157(6):718-31. PubMed ID: 22533681
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
Yi JM; Zhang XF; Huan XJ; Song SS; Wang W; Tian QT; Sun YM; Chen Y; Ding J; Wang YQ; Yang CH; Miao ZH
Oncotarget; 2015 Apr; 6(11):8960-73. PubMed ID: 25840421
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Golay J; Cuppini L; Leoni F; Micò C; Barbui V; Domenghini M; Lombardi L; Neri A; Barbui AM; Salvi A; Pozzi P; Porro G; Pagani P; Fossati G; Mascagni P; Introna M; Rambaldi A
Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
[TBL] [Abstract][Full Text] [Related]
17. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
Zheng Y; Yang J; Qian J; Zhang L; Lu Y; Li H; Lin H; Lan Y; Liu Z; He J; Hong S; Thomas S; Shah J; Baladandayuthapani V; Kwak LW; Yi Q
J Mol Med (Berl); 2012 Jun; 90(6):695-706. PubMed ID: 22207485
[TBL] [Abstract][Full Text] [Related]
18. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
Schueler J; Wider D; Klingner K; Siegers GM; May AM; Wäsch R; Fiebig HH; Engelhardt M
PLoS One; 2013; 8(11):e79939. PubMed ID: 24223204
[TBL] [Abstract][Full Text] [Related]
19. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
20. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
